Bakkenolide BCAS# 18455-98-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 18455-98-6 | SDF | Download SDF |
PubChem ID | 11165211 | Appearance | Powder |
Formula | C22H30O6 | M.Wt | 390.47 |
Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(2R,3R,3aR,4S,7S,7aR)-3-acetyloxy-7,7a-dimethyl-4'-methylidene-2'-oxospiro[3,3a,4,5,6,7-hexahydro-1H-indene-2,3'-oxolane]-4-yl] (Z)-2-methylbut-2-enoate | ||
SMILES | CC=C(C)C(=O)OC1CCC(C2(C1C(C3(C2)C(=C)COC3=O)OC(=O)C)C)C | ||
Standard InChIKey | AVAGQVZSHJYDED-RRIKAWJQSA-N | ||
Standard InChI | InChI=1S/C22H30O6/c1-7-12(2)19(24)28-16-9-8-13(3)21(6)11-22(14(4)10-26-20(22)25)18(17(16)21)27-15(5)23/h7,13,16-18H,4,8-11H2,1-3,5-6H3/b12-7-/t13-,16-,17+,18+,21+,22+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Bakkenolide B has suppressive properties for allergic and inflammatory responses and may be utilized as a potent agent for the treatment of asthma. |
Targets | NOS | COX |
Bakkenolide B Dilution Calculator
Bakkenolide B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.561 mL | 12.8051 mL | 25.6102 mL | 51.2203 mL | 64.0254 mL |
5 mM | 0.5122 mL | 2.561 mL | 5.122 mL | 10.2441 mL | 12.8051 mL |
10 mM | 0.2561 mL | 1.2805 mL | 2.561 mL | 5.122 mL | 6.4025 mL |
50 mM | 0.0512 mL | 0.2561 mL | 0.5122 mL | 1.0244 mL | 1.2805 mL |
100 mM | 0.0256 mL | 0.1281 mL | 0.2561 mL | 0.5122 mL | 0.6403 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Madecassic acid
Catalog No.:BCN1013
CAS No.:18449-41-7
- Gefitinib hydrochloride
Catalog No.:BCC1591
CAS No.:184475-55-6
- Gefitinib
Catalog No.:BCN2173
CAS No.:184475-35-2
- Cucurbitacin E
Catalog No.:BCN2300
CAS No.:18444-66-1
- Vitisin B
Catalog No.:BCN6697
CAS No.:142449-90-9
- Picfeltarraenin IV
Catalog No.:BCN2852
CAS No.:184288-35-5
- Dihydromorin
Catalog No.:BCN1149
CAS No.:18422-83-8
- SR 142948
Catalog No.:BCC7323
CAS No.:184162-64-9
- GB 2a
Catalog No.:BCN7425
CAS No.:18412-96-9
- Hautriwaic acid
Catalog No.:BCN4686
CAS No.:18411-75-1
- Isoleojaponin
Catalog No.:BCN7442
CAS No.:1840966-49-5
- Calystegine B4
Catalog No.:BCN1881
CAS No.:184046-85-3
- 1-Oxobakkenolide S
Catalog No.:BCN7114
CAS No.:18456-02-5
- Bakkenolide D
Catalog No.:BCN2909
CAS No.:18456-03-6
- Taxinine B
Catalog No.:BCN1150
CAS No.:18457-44-8
- 7-Deacetoxytaxinine J
Catalog No.:BCN7677
CAS No.:18457-45-9
- Taxinine J
Catalog No.:BCN6943
CAS No.:18457-46-0
- ROS 234 dioxalate
Catalog No.:BCC7245
CAS No.:184576-87-2
- Mangostanol
Catalog No.:BCN1151
CAS No.:184587-72-2
- Ethyl Coumarin-3-Carboxylate
Catalog No.:BCC9228
CAS No.:1846-76-0
- Nigracin
Catalog No.:BCN1152
CAS No.:18463-25-7
- 2-C-Methyl-D-erythrono-1,4-lactone
Catalog No.:BCN4769
CAS No.:18465-71-9
- Pelargonidin-3-O-glucoside chloride
Catalog No.:BCN3113
CAS No.:18466-51-8
- NAD 299 hydrochloride
Catalog No.:BCC6003
CAS No.:184674-99-5
Anti-allergic and anti-inflammatory effects of bakkenolide B isolated from Petasites japonicus leaves.[Pubmed:23711828]
J Ethnopharmacol. 2013 Jul 30;148(3):890-4.
AIMS OF THE STUDY: To elucidate the anti-allergic and anti-inflammatory effects of Petasites genus, we studied the effects of several compounds isolated from Petasites japonicas leaves. MATERIALS AND METHODS: Bakkenolide B was isolated from Petasites japonicus leaves. Antigen-induced degranulation was measured in RBL-2H3 mast cells by measuring beta-hexosamidase activity. Induction of inducible nitric oxide synthase and cyclooxygenase 2 was measured by Western blotting in peritoneal macrophages. Ovalbumin-induced asthma model was used for in vivo efficacy test of bakkanolide B. RESULTS: We found that Bakkenolide B, a major component of the leaves, concentration-dependently inhibited RBL-2H3 mast cell degranulation. Bakkenolide B also inhibited the gene inductions of inducible nitric oxide synthase and cyclooxygenase 2 in mouse peritoneal macrophages. Furthermore, in an ovalbumin-induced asthma model, Bakkenolide B strongly inhibited the accumulation of eosinophils, macrophages, and lymphocytes to bronchoalveolar lavage fluid. CONCLUSION: Bakkenolide B has suppressive properties for allergic and inflammatory responses and may be utilized as a potent agent for the treatment of asthma.